Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 12:50 PM ISTYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
AI can predict premature deaths in people with inflammatory bowel disease, suggests study Dr. Kamal Kant Kohli24 March 2025 6:30 AM ISTAlmost half of people who died with inflammatory bowel disease (IBD) died prematurely, according to a study published in CMAJ (Canadian Medical...
Inflammatory Bowel Disease Linked to Increased Stroke Risk, claims study Dr Riya Dave28 Feb 2025 7:45 AM ISTA new study published in BMC Gastroenterology identified that patients with inflammatory bowel disease (IBD), such as Crohn's disease (CD) and...
Biocon Biologics unveils Yesintek biosimilar to Stelara in US Ruchika Sharma25 Feb 2025 12:31 PM ISTYESINTEK will be available in all the same formulations currently provided by Stelara.
Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis Ruchika Sharma7 Feb 2025 11:30 AM ISTBengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global biopharmaceutical company, have...
Genetic Study Links Anterior Uveitis to Autoimmune Diseases Dr. Kamal Kant Kohli31 Jan 2025 8:30 PM ISTAn international study led by the University of Oulu and Oulu University Hospital has identified six genetic regions associated with inflammation of...
Wearable devices can detect and predict inflammatory bowel disease flare-ups, Mount Sinai study finds Dr. Kamal Kant Kohli17 Jan 2025 9:45 PM ISTWearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in inflammatory bowel disease...
CDSCO panel approves Sanofi's proposal to increase number of subjects from 25 to 40 in india to study SAR443122 Dr. Divya Colin5 Jan 2025 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug...
JnJ seeks USFDA approval for Simponi to treat pediatric ulcerative colitis Ruchika Sharma19 Dec 2024 12:42 PM ISTDeveloped by Johnson & Johnson, SIMPONI is an anti-TNF biologic medicine that targets and blocks a protein called TNF-alpha.
USFDA approves Biocon Biologics Yesintek for Crohn's disease, Ulcerative Colitis, Plaque Psoriasis, Psoriatic Arthritis Ruchika Sharma2 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the U.S. Food ...
JnJ seeks USFDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis Ruchika Sharma29 Nov 2024 11:30 AM ISTSpring House: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
First American Gastroenterological Association living guideline for moderate-to-severe ulcerative colitis Dr. Kamal Kant Kohli26 Nov 2024 8:15 PM ISTThe American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe...
